Industry Insights AI
This week’s round of insights highlights three of the latest advancements in the application of artificial intelligence (AI) in healthcare.
AI-supported mammography can improve cancer detection
Recent findings published in The Lancet showed that AI-supported mammography screening can detect breast cancers more effectively than standard double reading. These findings are particularly timely as World Cancer Day in February underscored once again the vital role of early detection in improving cancer outcomes. In a study of more than 105,000 women in Sweden, AI-supported screening achieved higher sensitivity and resulted in 12% fewer interval cancers. An interval cancer is diagnosed after a negative screening test but before the next routine exam. Importantly, AI was able to reduce workload, allowing specialists to focus on complex cases.
Study abstract: https://shorturl.at/a0iCs
OpenAI launches healthcare-focused AI tools
OpenAI has introduced a new suite of healthcare AI tools, including ChatGPT for Healthcare. These tools were designed to simplify clinical workflows and reduce administrative burden. According to Open AI, the tools support HIPAA compliance and enable clinicians to interpret medical evidence, draft documentation, and tailor patient education materials. Early users have reported improved efficiency and more time for patient care. The creators, however, also stressed that ethical oversight and careful validation remain necessary when using these tools.
Press release: https://openai.com/index/openai-for-healthcare/
How can AI target inefficiencies in clinical trial design?
High failure rates in clinical trials remain a major challenge for drug development. In a recent interview with PharmExec, Angela Schwab, Trialynx founder and CEO, explained how AI offers an opportunity to rethink trial design. According to Schwab, effective AI platforms do not act as generic ‘chatbot’ solutions; instead, they implement expertise and guide teams step by step through protocol development. This structured approach may help improve trial feasibility, patient experience, and ultimately, scientific and commercial success.
Interview: https://shorturl.at/vSCht
